FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Described is a group of inventions involving the use of a malignant tumour-immunocytokine, containing a version of IL-2, and an antibody which binds to human PD-L1, for treating cancer or for preventing or treating metastases, using a combination of a malignant tumour-immunocytokine containing a variant IL-2, and an antibody which binds to human PD-L1, to inhibit the growth of a malignant tumour which expresses a target for immunocytokine, and/or increasing the median and/or overall survival of individuals having a malignant tumour expressing a target for immunocytokine, using a combination of a carcinoembiral antigen (CEA)-indeed immunocytokine containing an IL-2 variant, and an antibody which binds to a human fibroblast activating protein (PD-L1), for inhibiting growth of a malignant tumour which expresses CEA, and/or increasing the median and/or overall survival of individuals having a malignant CEA-expressing tumour, using a combination of a fibroblast activating protein (FAP) -based immunocytokine comprising an IL-2 variant, and an antibody which binds to human PD-L1, for inhibiting the growth of a malignant tumour which expresses FAP, and/or increasing the median and/or overall survival of individuals having a malignant tumour expressing FAP, a combination of a malignant tumour-bound immunocytokine comprising a variant IL-2, and an antibody which binds to human PD-L1 for treating cancer, a combination of a malignant tumour-immunocytokine containing an IL-2 variant, and an antibody which binds to human PD-L1, for treating a patient having a CEA-expressing malignant tumour or malignant tumour, characterized by expression or overexpression of CEA having a FAP-expressing malignant tumour or a malignant tumour characterized by FAP expression or overexpression, or a malignant tumour associated with CEA or FAP expression or overexpression.
EFFECT: invention expands the arsenal of cancer treatments.
18 cl, 8 dwg, 11 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BISPECIFIC ANTIGEN-BINDING MOLECULES WITH CAPABILITY OF SPECIFICALLY BINDING TO CD40 AND FAP | 2018 |
|
RU2766234C2 |
| ANTI-PD-L1 AND IL-2 CYTOKINES | 2017 |
|
RU2769282C2 |
| PD-L1 SPECIFIC ANTIBODIES | 2017 |
|
RU2756236C2 |
| BISPECIFIC ANTIGEN-BINDING MOLECULES CONTAINING ANTI-FAP CLONE 212 | 2019 |
|
RU2799429C2 |
| BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING CD137 AND TUMOR ANTIGENS AND VARIANTS OF THEIR APPLICATION | 2018 |
|
RU2805648C2 |
| ANTI-ICOS ANTIBODIES | 2017 |
|
RU2764548C2 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| IMMUNOCYTOKIN INCLUDING A HETERODIMERIC PROTEIN COMPLEX BASED ON ОСНОВЕ IL-15/IL-15Rα AND ITS APPLICATION | 2019 |
|
RU2753282C2 |
| IMMUNOCONJUGATES OF DIRECTIVE EFFECT | 2010 |
|
RU2583876C2 |
| IL-12 COMPOSITIONS AIMED AT EDB | 2019 |
|
RU2758143C1 |
